LifeStance Health Group Reports Q3 Revenue Up 16% to $363.8 Million
Reuters
Nov 06, 2025
<a href="https://laohu8.com/S/LFST">LifeStance Health</a> Group Reports Q3 Revenue Up 16% to $363.8 Million
LifeStance Health Group Inc. reported third quarter 2025 revenue of $363.8 million, up 16% from the prior year, driven by increased visit volumes from net clinician growth and improved clinician productivity. Net income for the quarter was $1.1 million, compared to a net loss of $6.0 million in the previous year. Center Margin rose 16% to $116.6 million, representing 32.0% of total revenue. Adjusted EBITDA increased 31% to $40.2 million, or 11.1% of total revenue. Cash flow from operations for the quarter was $27.3 million, with a cash balance of $203.9 million and net long-term debt of $269.4 million at quarter end. The company reported free cash flow of $17.0 million. LifeStance reiterated its full year 2025 revenue guidance of $1.41 billion to $1.43 billion, raised its Center Margin midpoint expectations to $448 million to $462 million, and increased its Adjusted EBITDA guidance to $146 million to $152 million. The company also noted 17% organic visit growth and a clinician team of approximately 8,000 as key business developments for the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeStance Health Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570094-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.